|
|
|
Volumn 17, Issue 11 Suppl 12, 2003, Pages 23-28
|
|
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
GEFITINIB;
MONOCLONAL ANTIBODY;
QUINAZOLINE DERIVATIVE;
BIOASSAY;
CHEMICALLY INDUCED DISORDER;
CLASSIFICATION;
DOSE RESPONSE;
DRUG ANTAGONISM;
FEMALE;
HEAD AND NECK TUMOR;
HOSPITALIZATION;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
OVARY TUMOR;
PHASE 2 CLINICAL TRIAL;
RASH;
REVIEW;
SURVIVAL;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
BIOLOGICAL MARKERS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS, PHASE II;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ENDPOINT DETERMINATION;
EXANTHEMA;
FEMALE;
HEAD AND NECK NEOPLASMS;
HUMANS;
LUNG NEOPLASMS;
OVARIAN NEOPLASMS;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
SEVERITY OF ILLNESS INDEX;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 1542438546
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (175)
|
|
References (17)
|
